Stocktoria
Zentalis Pharmaceuticals, Inc. ZNTL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-04-03
Zentalis Pharmaceuticals, Inc. statistics & valuation
Market cap$250.6M
P / B1.2×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -283.6% | — | — | — |
| Net margin | — | -246.0% | — | — | — |
| FCF margin | — | -253.7% | — | — | — |
| Return on assets | -47.4% | -38.5% | -53.0% | -43.9% | -34.9% |
| Return on equity | -63.4% | -49.2% | -66.8% | -54.6% | -43.5% |
| Current ratio | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 |
| Revenue growth | -100.0% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001725160 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.